Remdesivir is emerging as an early leader in the quest for antiviral medications against SARS-CoV-2, the virus causing COVID-19. Overall mortality in treated patients was 13%, lower than in previously published studies of non-treated COVID-19 patients with serious symptoms.
Results from a clinical study showed that clinical improvement was observed in 68% of patients (36 of 53). The trial’s findings, funded by the drug’s manufacturer Gilead Sciences, were published in the New England Journal of Medicine.
